Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line
Berlin, Germany, July 13, 2021: ProBioGen announced today that they have entered into a research license agreement with Heat Biologics for both ProBioGen's Transposase System..
ProBioGen and LAVA Therapeutics N.V. sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific
Berlin, Germany and Utrecht, Netherlands, June 22, 2021: ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a..
City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform
Berlin, Germany and Duarte, USA, June 9, 2021: ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and..
ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company
Berlin, Germany and Cairo, Egypt, May 27, 2021: ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin..
ProBioGen und Minapharm Pharmaceuticals gründen die MiGenTra GmbH mit dem Ziel, das Gesundheitswesen zu verändern
Berlin, Deutschland und Kairo, Ägypten, 27. Mai 2021: ProBioGen und Minapharm Pharmaceuticals geben die Gründung von ProBioGens Tochtergesellschaft "MiGenTra" bekannt. Die neue..
Asher Biotherapeutics contracts ProBioGen to develop and manufacture their Lead Candidate
Berlin, Germany, April 26, 2021: ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development,..
Nouscom activates Commercial Product License for ProBioGen’s proprietary Vaccine Production Cell Line AGE1.CR.pIX®
Berlin, Germany, April 15, 2021: ProBioGen announced today that Nouscom has activated a commercial product license to ProBioGen's innovative, cell-based vaccine platform..
Dr. Simon Bulling Joins ProBioGen as Chief Operating Officer to Drive Next Phase of Operational Growth
Apr 21, 2026
ProBioGen Introduces CMC Navigator™ to Help Biopharma Teams Select the Best CMC Path Forward
Feb 17, 2026
ProBioGen and Zag Bio™ Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy
Jan 6, 2026
ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101
Dec 9, 2025
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Oct 10, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-2.webp)
ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services
May 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
